NRAS and non-small cell lung carcinoma: The growing interest in RAS genes, particularly K-ras and N-ras, in colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC) patients is related to their potential as predictive biomarkers of response or resistance to targeted therapy.